Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNTX-4975 in osteoarthritis knee pain
NCT02558439Phase 2
Key facts
- Status
- Completed
- Start
- Aug 2015
- Primary completion
- Oct 2016
- Countries
- 1
- Sponsor
- Centrexion Therapeutics
- Modality
- Small Molecules
- Drugs
- capsaicin
- Conditions
- osteoarthritis (OA)
01
Overview
Phase 2, randomised, double-blind trial of capsaicin in osteoarthritis (OA) (3 arms), sponsored by Centrexion Therapeutics. Primary endpoint: Change from Baseline in Average Knee Index Pain with Walking (WOMAC A1) at 12 weeks. Started Aug 2015; status: completed.
02
Design
3 arms- Study design
- RandomizedDouble-blind
Placebo
Single injection of placebo.
0.5 mg CNTX-4975
Single injection of 0.5 mg CNTX-4975.
1.0 mg CNTX-4975
Single injection of 1.0 mg CNTX-4975.
03
Endpoints
Primary
Change from Baseline in Average Knee Index Pain with Walking (WOMAC A1)
Secondary
Change from Baseline in Average Knee Index Pain with Walking (WOMAC A1)
Beyond the preview
Go deeper on NCT02558439.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02558439.